T-DXd binds HER2 (not topoisomerase I), is internalized, and releases deruxtecan that inhibits topoisomerase I to cause DNA damage and apoptosis; any killing of topoisomerase I–expressing cells occurs only if they receive the payload (e.g., bystander effect), not because they express topoisomerase I.